Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis

Nizar M. Tannir, Camillo Porta, Viktor Gruenwald, Toni K. Choueiri, Qasim Ahmad, Marlene Carrasco Alfonso, Luca Dezzani, Jackie Han, Cora N. Sternberg

The University of Texas MD Anderson Cancer Center, Houston, TX
IRCCS San Matteo University Hospital Foundation, Padua, Italy
Medical School of Hannover, Hannover, Germany
Dana-Farber Cancer Institute and Brigham and Women‘s Hospital, Boston, MA
Novartis Pharmaceuticals Corporation, East Hanover, NJ
San Camillo Forlanini Hospital, Rome, Italy